查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566068

ELISpot 和 FluoroSpot 检测的全球市场 - 全球规模、份额、趋势分析、机会、预测，2019-2030 年

Global ELISpot and FluoroSpot Assay Market, By Product; By Assay Type; By Source; By Disease; By Application; By End User; By Region, Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 710 Pages | 商品交期: 2-3个工作天内

价格
简介目录

ELISpot 和 FluoroSpot 检测的全球市场规模将以 7.6% 的复合年增长率成长，到 2030 年达到 4.795 亿美元

由于对灵敏和特异性检测的需求不断增加以及生物技术的进步，全球 ELISpot 和 FluoroSpot 检测市场正在蓬勃发展。

在最近的一项研究中，领先的策略咨询和市场研究公司 BlueWeave Consulting 估计 2023 年全球 ELISpot 和 FluoroSpot 检测市场规模将达到 2.898 亿美元。 BlueWeave 预测，2024-2030 年期间，全球 ELISpot 和 FluoroSpot Assay 市场规模将以 7.60% 的复合年增长率成长，到 2030 年达到 4.795 亿美元。有几个因素促进了市场的成长，包括慢性病的流行、新感染疾病的出现以及预防感染疾病的疫苗需求的不断增加。此外，预计该公司的技术进步也将在预测期内推动全球 ELISpot 和 FluoroSpot 检测市场。

机会－感染疾病流行加剧

疟疾、利什曼原虫症和爱滋病毒/爱滋病等各种感染疾病的全球盛行率不断上升，直接推动了对 ELISpot 和 Fluorospot 检测的需求。由于全球癌症负担不断增加以及早期检测的需求不断增加，癌症也占据了重要的市场占有率。

地缘政治紧张局势加剧对全球 ELISpot 和 FluoroSpot 检测市场的影响

地缘政治紧张局势的加剧可能会对全球 ELISpot 和 FluoroSpot 检测市场的成长产生负面影响。紧张局势升级可能导致贸易限制和製裁，从而限制实验所需试剂和设备的供应。研发项目的投资可能会减少，新产品的推出可能会被推迟。地缘政治不稳定可能会减少对我们生物技术业务的投资，导致新检测开发的资金筹措减少，并延迟我们的 ELISpot 和 FluoroSpot 技术的改进。政府可能会对生物产品和研究实施更严格的监管，从而影响新检测方法的核准流程和市场准入。战争和不稳定地区可能会关注医疗保健和诊断，从而增加对检测感染疾病和免疫反应的检测的需求。

诊断应用领域占最大市场占有率

诊断应用类别占据市场大部分，预计在预测期内将快速成长。用于疾病早期检测的先进试剂套件的开发和许多感染疾病的流行正在推动诊断领域的扩展。然而，研究应用市场也在显着成长，特别是考虑到 COVID-19 大流行。全球 ELISpot 和 FluoroSpot 检测市场的其他主要应用领域包括研究应用。

亚太地区将以全球市场最快的复合年增长率成长

预计亚太地区在预测期内将以最快的复合年增长率成长。新兴经济体的人口远多于已开发国家，因此，患有各种慢性病和感染疾病的人口比例也较高。因此，ELISpot 和 FluoroSpot 检测市场在亚太地区获得了巨大的关注。此外，预计中国仍将是亚太地区成长最快的市场。

竞争格局

全球 ELISpot 和 FluoroSpot 检测市场竞争激烈，许多公司都在争夺重要的市场占有率。市场主要参与者包括：OxfordImmunotecUSA, Inc.、BD、R&D Systems, Inc.、Mabtech、Thermo Fisher Scientific、Covalab, Inc.、Autoimmun Diagnost、ika GmbH、Abcam Limited、Labcorp Drug Development、Cellular Technology Limited、U - CyTech、Bio -Techne、Mikrogen GmbH 等

为了进一步增加市场占有率，这些公司正在采取各种策略，例如併购、伙伴关係、合资、授权合约和新产品发布。

该报告的详细分析提供了成长潜力、未来趋势以及有关全球 ELISpot 和 FluoroSpot 检测市场的资讯。它还涵盖了推动市场总规模预测的因素。该报告致力于提供全球 ELISpot 和 FluoroSpot 检测市场的最新技术趋势和产业见解，以帮助决策者做出明智的策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第三章全球 ELISpot 和 FluoroSpot 检测市场洞察

  • 产业价值链分析
    • DROC分析
    • 生长促进因子
      • 对灵敏和特异性检测的需求不断增长
      • 生物技术的进步
      • 慢性病增加
      • 扩大免疫学研究活动
    • 抑制因素
      • 高成本
      • 技术复杂性
      • 试剂供应有限
    • 机会
      • 应用程式扩充
      • 新兴市场
      • 与其他技术集成
    • 任务
      • 来自替代技术的竞争
      • 监管障碍
      • 道德考虑
  • 科技进步/最新趋势
  • 法律规范
  • 波特五力分析

第四章全球 ELISpot 和 FluoroSpot 检测市场：行销策略

第五章全球 ELISpot 和 FluoroSpot 检测市场概述

  • 2019-2030年市场能源容量及预测
    • 按金额
  • 市场占有率及预测
    • 副产品
      • 检测试剂套件
      • T细胞检测
      • B细胞检测
      • 分析仪
      • 补充或辅助产品
    • 按检测类型
      • ELISpot 检测试剂套件
      • FluoroSpot 检测试剂套件
    • 供应商
      • 人类
      • 老鼠
      • 猴
      • 其他的
    • 按疾病分类
      • 感染疾病
      • 癌症
      • 自体免疫疾病
      • 过敏
      • 其他的
    • 按申请
      • 诊断应用
      • 调查申请
    • 按最终用户
      • 医院和临床实验室
      • 调查机构
      • 生物製药公司
      • 其他的
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲（中东/非洲）

第六章 北美 ELISpot 和 FluoroSpot 分析市场

  • 2019-2030年市场能源容量及预测
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按检测类型
    • 供应商
    • 按疾病分类
    • 按申请
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第七章欧洲ELISpot与FluoroSpot分析市场

  • 2019-2030年市场能源容量及预测
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按检测类型
    • 供应商
    • 按疾病分类
    • 按申请
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第八章亚太地区 ELISpot 和 FluoroSpot 检测市场

  • 2019-2030年市场能源容量及预测
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按检测类型
    • 供应商
    • 按疾病分类
    • 按申请
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他国家

第九章 拉丁美洲 ELISpot 和 FluoroSpot 检测市场

  • 2019-2030年市场能源容量及预测
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按检测类型
    • 供应商
    • 按疾病分类
    • 按申请
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第10章中东和非洲ELISpot和FluoroSpot分析市场

  • 2019-2030年市场能源容量及预测
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按检测类型
    • 供应商
    • 按疾病分类
    • 按申请
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 中东和非洲其他地区

第十一章竞争格局

  • 主要企业及其产品列表
  • 2023年全球ELISpot与FluoroSpot检测公司市场占有率分析
  • 透过管理参数进行竞争基准基准化分析
  • 重大策略发展（合併、收购、联盟等）

第 12 章 地缘政治紧张局势加剧对全球 ELISpot 和 FluoroSpot 检测市场的影响

第十三章 公司简介（公司简介、财务矩阵、竞争格局、关键人员、主要竞争对手、联络方式、策略展望、SWOT分析）

  • Oxford Immunotec USA, Inc.
  • BD
  • R&D Systems, Inc.
  • Mabtech
  • Thermo Fisher Scientific
  • Covalab, Inc.
  • Autoimmun Diagnostika GmbH
  • Abcam Limited
  • Labcorp Drug Development
  • Cellular Technology Limited
  • U-CyTech
  • Bio-Techne
  • Mikrogen GmbH
  • 其他主要企业

第十四章 主要策略建议

第十五章调查方法

简介目录
Product Code: BWC24713

Global ELISpot and FluoroSpot Assay Market Size Expands at CAGR of 7.6% to Reach USD 479.5 Million by 2030

Global ELISpot and FluoroSpot Assay Market is flourishing because of the growing demand for sensitive and specific assays and advancements in biotechnology.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global ELISpot and FluoroSpot Assay Market size at USD 289.80 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global ELISpot and FluoroSpot Assay Market size to expand at a CAGR of 7.60% reaching a value of USD 479.50 million by 2030. Several factors contribute to the market growth, including the rising prevalence of chronic diseases, the emergence of new infectious diseases, and the growing demand for vaccines to prevent infectious diseases. Companies' technological advancements are also expected to drive Global ELISpot and FluoroSpot Assays Market over the forecast period.

Opportunity - Increasing Prevalence of Infectious Diseases

The rising prevalence of various infectious diseases, such as malaria, leishmaniasis, and HIV-AIDS, globally is directly propelling the demand for ELISpot and fluoroSport assays. Cancer also covers a significant market share owing to the growing burden of cancer worldwide and the rising need for its early detection.

Impact of Escalating Geopolitical Tensions on Global ELISpot and FluoroSpot Assay Market

Escalating geopolitical tensions could negatively impact the growth of Global ELISpot and FluoroSpot Assay Market. Increased tensions may result in trade restrictions or sanctions, limiting the supply of reagents and equipment required for these experiments. It might reduce investments in R&D programs and delay new product launches. Geopolitical instability might inhibit investment in biotech businesses, resulting in less financing for new assay development, thereby slowing improvements in ELISpot and FluoroSpot technologies. Governments may place more stern controls on biological goods and research, affecting the approval procedure and market entrance of novel assays. In areas of war or instability, there may be a greater emphasis on healthcare and diagnostics, which might increase demand for assays to detect infectious illnesses or immunological responses.

Diagnostics Application Segment Holds Largest Market Share

The diagnostic applications category accounts for the majority of the market and is anticipated to grow at a rapid rate over the course of the forecast period. The development of sophisticated kits for the early identification of illnesses and the increased prevalence of numerous infectious diseases are driving expansion in the diagnostic segment. However, the market for research applications is also growing significantly, particularly in light of the COVID-19 pandemic. Other major application segments of Global ELISpot and FluoroSpot Assay Market include research applications.

Asia Pacific to Grow at Fastest CAGR in Global Market

The Asia Pacific region is projected to record growth at the fastest CAGR over the forecast period. The population of emerging economies is much higher as compared to the developed countries, due to which the percentage of population suffering from various chronic and infectious diseases is also high. As a result, the ELISpot and FluoroSpot Assays Market is gaining significant traction in the Asia Pacific region. Moreover, China is projected to remain among the fastest-growing markets in the APAC region.

Competitive Landscape

Global ELISpot and FluoroSpot Assay Market is intensely competitive, as a number of companies are competing to gain a significant market share. Key players in the market include Oxford Immunotec USA, Inc., BD, R&D Systems, Inc., Mabtech, Thermo Fisher Scientific, Covalab, Inc., Autoimmun Diagnostika GmbH, Abcam Limited, Labcorp Drug Development, Cellular Technology Limited, U-CyTech, Bio-Techne, and Mikrogen GmbH.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global ELISpot and FluoroSpot Assay Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global ELISpot and FluoroSpot Assay Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global ELISpot and FluoroSpot Assay Market Insights

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. DROC Analysis
    • 3.1.2. Growth Drivers
      • 3.1.2.1. Growing Demand for Sensitive and Specific Assays
      • 3.1.2.2. Advancements in Biotechnology
      • 3.1.2.3. Increasing Prevalence of Chronic Diseases
      • 3.1.2.4. Growing Research Activities in Immunology
    • 3.1.3. Restraints
      • 3.1.3.1. High Costs
      • 3.1.3.2. Technical Complexity
      • 3.1.3.3. Limited Availability of Reagents
    • 3.1.4. Opportunities
      • 3.1.4.1. Expanding Applications
      • 3.1.4.2. Emerging Markets
      • 3.1.4.3. Integration with Other Technologies
    • 3.1.5. Challenges
      • 3.1.5.1. Competition from Alternative Technologies
      • 3.1.5.2. Regulatory Hurdles
      • 3.1.5.3. Ethical Considerations
  • 3.2. Technological Advancements/Recent Developments
  • 3.3. Regulatory Framework
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of New Entrants
    • 3.4.4. Threat of Substitutes
    • 3.4.5. Intensity of Rivalry

4. Global ELISpot and FluoroSpot Assay Market: Marketing Strategies

5. Global ELISpot and FluoroSpot Assay Market Overview

  • 5.1. Market Energy Capacity & Forecast, 2019-2030
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Assay Kits
      • 5.2.1.1.1. T Cell assay
      • 5.2.1.1.2. B Cell assay
      • 5.2.1.2. Analysers
      • 5.2.1.3. Supplementary or Ancillary Products
    • 5.2.2. By Assay Type
      • 5.2.2.1. ELISpot Assay Kits
      • 5.2.2.2. FluoroSpot Assay Kits
    • 5.2.3. By Source
      • 5.2.3.1. Human
      • 5.2.3.2. Mouse
      • 5.2.3.3. Monkey
      • 5.2.3.4. Others
    • 5.2.4. By Diseases
      • 5.2.4.1. Infectious Diseases
      • 5.2.4.2. Cancer
      • 5.2.4.3. Autoimmune Diseases
      • 5.2.4.4. Allergy
      • 5.2.4.5. Others
    • 5.2.5. By Application
      • 5.2.5.1. Diagnostic Applications
      • 5.2.5.2. Research Applications
    • 5.2.6. By End User
      • 5.2.6.1. Hospitals & Clinical Laboratories
      • 5.2.6.2. Research Institutes
      • 5.2.6.3. Biopharmaceutical Companies
      • 5.2.6.4. Others
    • 5.2.7. By Region
      • 5.2.7.1. North America
      • 5.2.7.2. Europe
      • 5.2.7.3. Asia Pacific (APAC)
      • 5.2.7.4. Latin America (LATAM)
      • 5.2.7.5. Middle East and Africa (MEA)

6. North America ELISpot and FluoroSpot Assay Market

  • 6.1. Market Energy Capacity & Forecast, 2019-2030
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Assay Type
    • 6.2.3. By Source
    • 6.2.4. By Diseases
    • 6.2.5. By Application
    • 6.2.6. By End User
    • 6.2.7. By Country
      • 6.2.7.1. United States
      • 6.2.7.1.1. By Product
      • 6.2.7.1.2. By Assay Type
      • 6.2.7.1.3. By Source
      • 6.2.7.1.4. By Diseases
      • 6.2.7.1.5. By Application
      • 6.2.7.1.6. By End User
      • 6.2.7.2. Canada
      • 6.2.7.2.1. By Product
      • 6.2.7.2.2. By Assay Type
      • 6.2.7.2.3. By Source
      • 6.2.7.2.4. By Diseases
      • 6.2.7.2.5. By Application
      • 6.2.7.2.6. By End User

7. Europe ELISpot and FluoroSpot Assay Market

  • 7.1. Market Energy Capacity & Forecast, 2019-2030
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Assay Type
    • 7.2.3. By Source
    • 7.2.4. By Diseases
    • 7.2.5. By Application
    • 7.2.6. By End User
    • 7.2.7. By Country
      • 7.2.7.1. Germany
      • 7.2.7.1.1. By Product
      • 7.2.7.1.2. By Assay Type
      • 7.2.7.1.3. By Source
      • 7.2.7.1.4. By Diseases
      • 7.2.7.1.5. By Application
      • 7.2.7.1.6. By End User
      • 7.2.7.2. United Kingdom
      • 7.2.7.2.1. By Product
      • 7.2.7.2.2. By Assay Type
      • 7.2.7.2.3. By Source
      • 7.2.7.2.4. By Diseases
      • 7.2.7.2.5. By Application
      • 7.2.7.2.6. By End User
      • 7.2.7.3. Italy
      • 7.2.7.3.1. By Product
      • 7.2.7.3.2. By Assay Type
      • 7.2.7.3.3. By Source
      • 7.2.7.3.4. By Diseases
      • 7.2.7.3.5. By Application
      • 7.2.7.3.6. By End User
      • 7.2.7.4. France
      • 7.2.7.4.1. By Product
      • 7.2.7.4.2. By Assay Type
      • 7.2.7.4.3. By Source
      • 7.2.7.4.4. By Diseases
      • 7.2.7.4.5. By Application
      • 7.2.7.4.6. By End User
      • 7.2.7.5. Spain
      • 7.2.7.5.1. By Product
      • 7.2.7.5.2. By Assay Type
      • 7.2.7.5.3. By Source
      • 7.2.7.5.4. By Diseases
      • 7.2.7.5.5. By Application
      • 7.2.7.5.6. By End User
      • 7.2.7.6. Belgium
      • 7.2.7.6.1. By Product
      • 7.2.7.6.2. By Assay Type
      • 7.2.7.6.3. By Source
      • 7.2.7.6.4. By Diseases
      • 7.2.7.6.5. By Application
      • 7.2.7.6.6. By End User
      • 7.2.7.7. Russia
      • 7.2.7.7.1. By Product
      • 7.2.7.7.2. By Assay Type
      • 7.2.7.7.3. By Source
      • 7.2.7.7.4. By Diseases
      • 7.2.7.7.5. By Application
      • 7.2.7.7.6. By End User
      • 7.2.7.8. The Netherlands
      • 7.2.7.8.1. By Product
      • 7.2.7.8.2. By Assay Type
      • 7.2.7.8.3. By Source
      • 7.2.7.8.4. By Diseases
      • 7.2.7.8.5. By Application
      • 7.2.7.8.6. By End User
      • 7.2.7.9. Rest of Europe
      • 7.2.7.9.1. By Product
      • 7.2.7.9.2. By Assay Type
      • 7.2.7.9.3. By Source
      • 7.2.7.9.4. By Diseases
      • 7.2.7.9.5. By Application
      • 7.2.7.9.6. By End User

8. Asia Pacific ELISpot and FluoroSpot Assay Market

  • 8.1. Market Energy Capacity & Forecast, 2019-2030
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Assay Type
    • 8.2.3. By Source
    • 8.2.4. By Diseases
    • 8.2.5. By Application
    • 8.2.6. By End User
    • 8.2.7. By Country
      • 8.2.7.1. China
      • 8.2.7.1.1. By Product
      • 8.2.7.1.2. By Assay Type
      • 8.2.7.1.3. By Source
      • 8.2.7.1.4. By Diseases
      • 8.2.7.1.5. By Application
      • 8.2.7.1.6. By End User
      • 8.2.7.2. India
      • 8.2.7.2.1. By Product
      • 8.2.7.2.2. By Assay Type
      • 8.2.7.2.3. By Source
      • 8.2.7.2.4. By Diseases
      • 8.2.7.2.5. By Application
      • 8.2.7.2.6. By End User
      • 8.2.7.3. Japan
      • 8.2.7.3.1. By Product
      • 8.2.7.3.2. By Assay Type
      • 8.2.7.3.3. By Source
      • 8.2.7.3.4. By Diseases
      • 8.2.7.3.5. By Application
      • 8.2.7.3.6. By End User
      • 8.2.7.4. South Korea
      • 8.2.7.4.1. By Product
      • 8.2.7.4.2. By Assay Type
      • 8.2.7.4.3. By Source
      • 8.2.7.4.4. By Diseases
      • 8.2.7.4.5. By Application
      • 8.2.7.4.6. By End User
      • 8.2.7.5. Australia & New Zealand
      • 8.2.7.5.1. By Product
      • 8.2.7.5.2. By Assay Type
      • 8.2.7.5.3. By Source
      • 8.2.7.5.4. By Diseases
      • 8.2.7.5.5. By Application
      • 8.2.7.5.6. By End User
      • 8.2.7.6. Indonesia
      • 8.2.7.6.1. By Product
      • 8.2.7.6.2. By Assay Type
      • 8.2.7.6.3. By Source
      • 8.2.7.6.4. By Diseases
      • 8.2.7.6.5. By Application
      • 8.2.7.6.6. By End User
      • 8.2.7.7. Malaysia
      • 8.2.7.7.1. By Product
      • 8.2.7.7.2. By Assay Type
      • 8.2.7.7.3. By Source
      • 8.2.7.7.4. By Diseases
      • 8.2.7.7.5. By Application
      • 8.2.7.7.6. By End User
      • 8.2.7.8. Singapore
      • 8.2.7.8.1. By Product
      • 8.2.7.8.2. By Assay Type
      • 8.2.7.8.3. By Source
      • 8.2.7.8.4. By Diseases
      • 8.2.7.8.5. By Application
      • 8.2.7.8.6. By End User
      • 8.2.7.9. Vietnam
      • 8.2.7.9.1. By Product
      • 8.2.7.9.2. By Assay Type
      • 8.2.7.9.3. By Source
      • 8.2.7.9.4. By Diseases
      • 8.2.7.9.5. By Application
      • 8.2.7.9.6. By End User
      • 8.2.7.10. Rest of APAC
      • 8.2.7.10.1. By Product
      • 8.2.7.10.2. By Assay Type
      • 8.2.7.10.3. By Source
      • 8.2.7.10.4. By Diseases
      • 8.2.7.10.5. By Application
      • 8.2.7.10.6. By End User

9. Latin America ELISpot and FluoroSpot Assay Market

  • 9.1. Market Energy Capacity & Forecast, 2019-2030
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Assay Type
    • 9.2.3. By Source
    • 9.2.4. By Diseases
    • 9.2.5. By Application
    • 9.2.6. By End User
    • 9.2.7. By Country
      • 9.2.7.1. Brazil
      • 9.2.7.1.1. By Product
      • 9.2.7.1.2. By Assay Type
      • 9.2.7.1.3. By Source
      • 9.2.7.1.4. By Diseases
      • 9.2.7.1.5. By Application
      • 9.2.7.1.6. By End User
      • 9.2.7.2. Mexico
      • 9.2.7.2.1. By Product
      • 9.2.7.2.2. By Assay Type
      • 9.2.7.2.3. By Source
      • 9.2.7.2.4. By Diseases
      • 9.2.7.2.5. By Application
      • 9.2.7.2.6. By End User
      • 9.2.7.3. Argentina
      • 9.2.7.3.1. By Product
      • 9.2.7.3.2. By Assay Type
      • 9.2.7.3.3. By Source
      • 9.2.7.3.4. By Diseases
      • 9.2.7.3.5. By Application
      • 9.2.7.3.6. By End User
      • 9.2.7.4. Peru
      • 9.2.7.4.1. By Product
      • 9.2.7.4.2. By Assay Type
      • 9.2.7.4.3. By Source
      • 9.2.7.4.4. By Diseases
      • 9.2.7.4.5. By Application
      • 9.2.7.4.6. By End User
      • 9.2.7.5. Rest of LATAM
      • 9.2.7.5.1. By Product
      • 9.2.7.5.2. By Assay Type
      • 9.2.7.5.3. By Source
      • 9.2.7.5.4. By Diseases
      • 9.2.7.5.5. By Application
      • 9.2.7.5.6. By End User

10. Middle East & Africa ELISpot and FluoroSpot Assay Market

  • 10.1. Market Energy Capacity & Forecast, 2019-2030
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Assay Type
    • 10.2.3. By Source
    • 10.2.4. By Diseases
    • 10.2.5. By Application
    • 10.2.6. By End User
    • 10.2.7. By Country
      • 10.2.7.1. Saudi Arabia
      • 10.2.7.1.1. By Product
      • 10.2.7.1.2. By Assay Type
      • 10.2.7.1.3. By Source
      • 10.2.7.1.4. By Diseases
      • 10.2.7.1.5. By Application
      • 10.2.7.1.6. By End User
      • 10.2.7.2. UAE
      • 10.2.7.2.1. By Product
      • 10.2.7.2.2. By Assay Type
      • 10.2.7.2.3. By Source
      • 10.2.7.2.4. By Diseases
      • 10.2.7.2.5. By Application
      • 10.2.7.2.6. By End User
      • 10.2.7.3. Qatar
      • 10.2.7.3.1. By Product
      • 10.2.7.3.2. By Assay Type
      • 10.2.7.3.3. By Source
      • 10.2.7.3.4. By Diseases
      • 10.2.7.3.5. By Application
      • 10.2.7.3.6. By End User
      • 10.2.7.4. Kuwait
      • 10.2.7.4.1. By Product
      • 10.2.7.4.2. By Assay Type
      • 10.2.7.4.3. By Source
      • 10.2.7.4.4. By Diseases
      • 10.2.7.4.5. By Application
      • 10.2.7.4.6. By End User
      • 10.2.7.5. South Africa
      • 10.2.7.5.1. By Product
      • 10.2.7.5.2. By Assay Type
      • 10.2.7.5.3. By Source
      • 10.2.7.5.4. By Diseases
      • 10.2.7.5.5. By Application
      • 10.2.7.5.6. By End User
      • 10.2.7.6. Nigeria
      • 10.2.7.6.1. By Product
      • 10.2.7.6.2. By Assay Type
      • 10.2.7.6.3. By Source
      • 10.2.7.6.4. By Diseases
      • 10.2.7.6.5. By Application
      • 10.2.7.6.6. By End User
      • 10.2.7.7. Algeria
      • 10.2.7.7.1. By Product
      • 10.2.7.7.2. By Assay Type
      • 10.2.7.7.3. By Source
      • 10.2.7.7.4. By Diseases
      • 10.2.7.7.5. By Application
      • 10.2.7.7.6. By End User
      • 10.2.7.8. Rest of MEA
      • 10.2.7.8.1. By Product
      • 10.2.7.8.2. By Assay Type
      • 10.2.7.8.3. By Source
      • 10.2.7.8.4. By Diseases
      • 10.2.7.8.5. By Application
      • 10.2.7.8.6. By End User

11. Competitive Landscape

  • 11.1. List of Key Players and Their Offerings
  • 11.2. Global ELISpot and FluoroSpot Assay Company Market Share Analysis, 2023
  • 11.3. Competitive Benchmarking, By Operating Parameters
  • 11.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

12. Impact of Escalating Geopolitical Tensions on Global ELISpot and FluoroSpot Assay Market

13. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 13.1. Oxford Immunotec USA, Inc.
  • 13.2. BD
  • 13.3. R&D Systems, Inc.
  • 13.4. Mabtech
  • 13.5. Thermo Fisher Scientific
  • 13.6. Covalab, Inc.
  • 13.7. Autoimmun Diagnostika GmbH
  • 13.8. Abcam Limited
  • 13.9. Labcorp Drug Development
  • 13.10. Cellular Technology Limited
  • 13.11. U-CyTech
  • 13.12. Bio-Techne
  • 13.13. Mikrogen GmbH
  • 13.14. Other Prominent Players

14. Key Strategic Recommendations

15. Research Methodology

  • 15.1. Qualitative Research
    • 15.1.1. Primary & Secondary Research
  • 15.2. Quantitative Research
  • 15.3. Market Breakdown & Data Triangulation
    • 15.3.1. Secondary Research
    • 15.3.2. Primary Research
  • 15.4. Breakdown of Primary Research Respondents, By Region
  • 15.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable